Throughout the last year, we’ve seen some of the most significant breakthroughs to date in Alzheimer’s disease research, most notably—solidifying that anti-Aβ is a viable and clinically-sound treatment pathway. This is only the beginning, and we at Prothena are both proud and excited to be a part of developing the next generation of therapies for this devastating disease.

“Over the last decade, particularly, we’ve witnessed an evolution across the Alzheimer’s space in which learnings from one company’s clinical trials inform the next set of studies – and in turn, the next. This is how science is supposed to work. No one company can solve a problem as big as Alzheimer’s disease alone. It takes an entire industry, a whole scientific community to do this,” noted Donna Masterman Vice President, Medical Affairs, Neuroscience Lead, in an op-ed published recently in Pharmaphorum.

She also discussed that earlier this year, Prothena had the honor of attending the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden. Understandably, the level of excitement around the latest R&D at the conference felt unlike any year prior—from data on potential new treatments on the horizon to discussion around exploring avenues for earlier diagnosis and monitoring of disease progression. During the AD/PD conference, Brian Campbell, Vice President, Head of Translational Medicine, delivered an oral presentation highlighting preclinical data from PRX012, a potential best-in class anti-Aβ product candidate in development for the treatment of Alzheimer’s disease.

As Donna noted, scientific exchange is imperative in the continued fight against this cruel disease. Trial results of other Aβ targeting drugs validate the mechanism designed by Prothena and provide insights that may shorten the path to patients for our next generation therapies. We look forward to participating in and collaborating at more conferences in the future.

 

For Donna Masterman’s full op-ed published in Pharmaphorum, click here.